As a pharmacist and healthcare entrepreneur, it truly grinds my gears when I see reputable PubMed articles twisted into sensational headlines that most followers will never read
In the trial mentioned above, one year after stopping the GLP-1 medication, participants also saw: Blood pressure levels go back up C-reactive protein levels (an indicator of inflammation) increase VLDL cholesterol (a type that leads to hardened arteries) goes up Triglycerides (a type of blood fat) go up Hemoglobin A1c increases (meaning the level of sugar in the blood) At high levels, these health markers are associated with conditions like type 2 diabetes, obesity, hypertension, and heart disease, to list a few
Eren-Yazicioglu CY et al
What are the conditions these drugs are intended to treat
As of February 2026, Eli Lilly plans to submit orforglipron for FDA approval as a diabetes treatment sometime in 2026
SUPER: STEP 5: INJECT THE DOSE Keep the button pressed, and slowly count to 10